CA2988299C - Endostatin fragments and variants for use in treating fibrosis - Google Patents

Endostatin fragments and variants for use in treating fibrosis Download PDF

Info

Publication number
CA2988299C
CA2988299C CA2988299A CA2988299A CA2988299C CA 2988299 C CA2988299 C CA 2988299C CA 2988299 A CA2988299 A CA 2988299A CA 2988299 A CA2988299 A CA 2988299A CA 2988299 C CA2988299 C CA 2988299C
Authority
CA
Canada
Prior art keywords
polypeptide
endostatin
fibrosis
seq
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2988299A
Other languages
English (en)
French (fr)
Other versions
CA2988299A1 (en
Inventor
Carol FEGHALI-BOSTWICK
Terence E RYAN
Hal S. Padgett
Matthew MCGEE
R. Barry Holtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Novici Biotech LLC
Ibio Inc
Original Assignee
MUSC Foundation for Research and Development
Novici Biotech LLC
Ibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development, Novici Biotech LLC, Ibio Inc filed Critical MUSC Foundation for Research and Development
Publication of CA2988299A1 publication Critical patent/CA2988299A1/en
Application granted granted Critical
Publication of CA2988299C publication Critical patent/CA2988299C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2988299A 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis Active CA2988299C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US62/171,889 2015-06-05
US201562257607P 2015-11-19 2015-11-19
US62/257,607 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Publications (2)

Publication Number Publication Date
CA2988299A1 CA2988299A1 (en) 2016-12-08
CA2988299C true CA2988299C (en) 2023-10-31

Family

ID=56236074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2988299A Active CA2988299C (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Country Status (10)

Country Link
US (2) US10844392B2 (enExample)
EP (1) EP3303383A1 (enExample)
JP (2) JP6952685B2 (enExample)
KR (1) KR20180033499A (enExample)
CN (2) CN107849117B (enExample)
AU (2) AU2016270428B2 (enExample)
BR (1) BR112017026209A2 (enExample)
CA (1) CA2988299C (enExample)
WO (1) WO2016197018A1 (enExample)
ZA (1) ZA201708223B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6952685B2 (ja) * 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント
EP3850003A1 (en) * 2018-09-14 2021-07-21 The Board of Trustees of the Leland Stanford Junior University Spd-1 variant - fc fusion proteins
US20210008173A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
EP3996694A1 (en) * 2019-07-31 2022-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
WO2022006601A1 (en) * 2020-07-02 2022-01-06 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
EP4251130A4 (en) * 2020-11-30 2024-12-11 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
IL311163A (en) * 2021-09-07 2024-04-01 Musc Found For Res Dev Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JP3039802B2 (ja) 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
CN1284134A (zh) 1997-12-08 2001-02-14 贝斯以色列护理医疗中心 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002517186A (ja) * 1998-06-03 2002-06-18 ザ チルドレンズ メディカル センター コーポレイション エンドスタチンタンパク質を含むタンパク質オリゴマー組成物およびその使用方法
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
JP2003517280A (ja) 1999-02-05 2003-05-27 トーマス・ジェファーソン・ユニバーシティ トランス相補性システムを用いての植物における生物医学用ペプチド及びタンパク質の生成
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP2173377B1 (en) * 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
US8507441B2 (en) 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
US20140057831A1 (en) * 2011-07-19 2014-02-27 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
JP6952685B2 (ja) 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント

Also Published As

Publication number Publication date
BR112017026209A2 (pt) 2018-11-27
CN107849117A (zh) 2018-03-27
US10844392B2 (en) 2020-11-24
WO2016197018A1 (en) 2016-12-08
EP3303383A1 (en) 2018-04-11
AU2021200765A1 (en) 2021-03-04
WO2016197018A9 (en) 2017-01-19
AU2016270428A1 (en) 2018-01-25
CA2988299A1 (en) 2016-12-08
JP6952685B2 (ja) 2021-10-20
ZA201708223B (en) 2018-11-28
US11912755B2 (en) 2024-02-27
KR20180033499A (ko) 2018-04-03
AU2021200765B2 (en) 2023-04-13
CN107849117B (zh) 2022-08-26
AU2016270428B2 (en) 2020-11-26
US20180179263A1 (en) 2018-06-28
CN115925878A (zh) 2023-04-07
JP2018524019A (ja) 2018-08-30
WO2016197018A8 (en) 2017-07-13
JP7404320B2 (ja) 2023-12-25
US20210108221A1 (en) 2021-04-15
JP2022002527A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
US11912755B2 (en) Endostatin fragments and variants for use in treating fibrosis
JP2010506860A (ja) Ｐ−糖タンパク質機能を刺激するための化合物およびその使用
CN104271147A (zh) 细胞穿膜肽
JP6772317B2 (ja) アポリポタンパク質模倣体及びその使用
WO2014165277A2 (en) POTENT AND SELECTIVE INHIBITORS OF Nav1.7
ZA200607492B (en) Y2/Y4 selective receptor agonists for therapeutic interventions
EP1786458A2 (en) Y2/y4 selective receptor agonists for therapeutic interventions
EP2797617B1 (en) Anti-tumor adjuvant therapy
CN119285744A (zh) 逆向-反转肽
WO2022111713A9 (zh) 一种含有二硫键且具有抑制丝氨酸蛋白酶活性的多肽、其衍生的杂交肽及其应用
US8278279B2 (en) Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
KR20160135742A (ko) 고리형 아펠린 유사체
CN114867527A (zh) 大环肽
WO2001090139A2 (en) A ligand for enhancing oral and cns delivery of biological agents
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
CN103044554A (zh) 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
WO2005095443A1 (ja) ペプチド改変を利用したドラッグデリバリーシステム
WO2004094462A2 (en) Methods of peptide preparation
EA011325B1 (ru) Высокоэффективные полные и частичные агонисты и антагонисты рецептора ноцицептина/орфанина fq

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210415

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325